RE:RE:RE:RE:DESPERATE BASHINGI agree Lith. We reportedly had that confidential agreement with a large insurer in the trial stage - that was over a year ago but no update - I can only assume that one didn't work out because there has been silence. Likewise there has been mention of the 40000 person workplace employer but no details. With Aristotle rolling out, we can go beyond Colonsentry and those same companies should be really interested now and I expect Tripp et al are actively engaging them for further trials etc. The cost savings thru early cancer identification is mammouth and that should make Aristotle a viable sell. I would love to see an NR not just announcing medical affiliations, but also the unmasking of a real insurer or large workplace employer because we all know what that would do to the sp.